Efficacy and safety of dapagliflozin according to baseline blood pressure - observations from DECLARE-TIMI 58 Trlial

被引：0
|
作者：
Furtado, R. [1 ]
Raz, I [2 ]
Goodrich, E. L. [3 ]
Sabatine, M. S. [3 ]
Wiviott, S. D. [3 ]
机构：
[1] Hosp Israelita Albert Einstein, Sao Paulo, Brazil
[2] Hebrew Univ Jerusalem, Hadassah Med Ctr, Diabet Unit, Jerusalem, Israel
[3] Harvard Med Sch, Brigham & Womens Hosp, TIMI Study Grp, Boston, MA 02115 USA
来源：
EUROPEAN HEART JOURNAL | 2020年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：3063 / 3063
页数：1
相关论文
共 50 条
  • [41] Cost-effectiveness analysis of dapagliflozin for the treatment of type 2 diabetes mellitus in Spain: results of the DECLARE-TIMI 58 study
    Escobar, Carlos
    Morales, Cristobal
    Capel, Margarita
    Simon, Susana
    Perez-Alcantara, Ferran
    Pomares, Elisenda
    BMC HEALTH SERVICES RESEARCH, 2022, 22 (01)
  • [42] Cardiovascular and renal benefits of dapagliflozin in patients with short and long-standing type 2 diabetes: Analysis from the DECLARE-TIMI 58 trial
    Bajaj, Harpreet S.
    Raz, Itamar
    Mosenzon, Ofri
    Murphy, Sabina A.
    Rozenberg, Aliza
    Yanuv, Ilan
    Bhatt, Deepak L.
    Leiter, Lawrence A.
    McGuire, Darren K.
    Wilding, John P. H.
    Gause-Nilsson, Ingrid A. M.
    Sabatine, Marc S.
    Wiviott, Stephen D.
    Cahn, Avivit
    DIABETES OBESITY & METABOLISM, 2020, 22 (07): : 1122 - 1131
  • [43] Dapagliflozin vermindert das Risiko für Krankenhausaufenthalte von Typ-2-Diabetes-PatientenNeue Ergebnisse aus der DECLARE-TIMI 58-StudieDapagliflozin reduces the risk for hospitalization in patients with type 2 diabetesNew results from the DECLARE-TIMI 58 trial
    Imke Schamarek
    Die Diabetologie, 2023, 19 (5) : 702 - 704
  • [44] Renal Outcomes from the DECLARE-TIMI 58 Trial: Quantifying the Health-Care Implications
    McEwan, Philip
    Kartman, Bernt
    Bennett, Hayley
    Edmonds, Christopher
    Gause-Nilsson, Ingrid Anna
    DIABETES, 2019, 68
  • [45] Risk of renal outcomes according to eGFR and categorical Urinary Albumin Creatinine Ratio (UACR) in the DECLARE-TIMI 58 trial
    Mosenzon, O.
    Wiviott, S. D.
    Yanuv, I.
    Cahn, A.
    Heerspink, H. J. L.
    Dwyer, J. P.
    Kato, E. T.
    Goodrich, E. L.
    Leiter, L. A.
    Bhatt, D. L.
    Langkilde, A.
    Fredriksson, M.
    Gause-Nilsson, I. A. M.
    Sabatine, M. S.
    Raz, I.
    DIABETOLOGIA, 2019, 62 : S486 - S486
  • [46] Reduced hospitalization for heart failure using anti-diabetic drug dapagliflozin: implications of DECLARE-TIMI 58 for the basic science community
    Kondo, Hidekazu
    Takahashi, Naohiko
    CARDIOVASCULAR RESEARCH, 2019, 115 (06) : E54 - E57
  • [47] Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLARE-TIMI 58 trial: A nationwide observational study
    Norhammar, Anna
    Bodegard, Johan
    Nystrom, Thomas
    Thuresson, Marcus
    Nathanson, David
    Eriksson, Jan W.
    DIABETES OBESITY & METABOLISM, 2019, 21 (05): : 1136 - 1145
  • [48] Cardiorenal and metabolic outcomes of dapagliflozin vs placebo in patients at high cardiovascular risk without established cardiovascular disease: analyses from the DECLARE-TIMI 58 study
    Cahn, A.
    Raz, I.
    Leiter, L. A.
    Mosenzon, O.
    Murphy, S. A.
    Bhatt, D. L.
    McGuire, D. K.
    Wilding, J. P. H.
    Gause-Nilsson, I. A. M.
    Langkilde, A.
    Sabatine, M.
    Wiviott, S. D.
    DIABETOLOGIA, 2020, 63 (SUPPL 1) : S269 - S269
  • [49] The Serendipitous Story of SGLT2 Inhibitors in Heart Failure New Insights From DECLARE-TIMI 58
    Verma, Subodh
    McMurray, John J. V.
    CIRCULATION, 2019, 139 (22) : 2537 - 2541
  • [50] Letter by Chen et al Regarding Article, "Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial"
    Chen, Zhi-Qing
    Chen, Feng
    Li, Lang
    CIRCULATION, 2020, 142 (10) : E127 - E128
12345